Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
Thalidomide-pyrrolidine-C-azaspiro is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation through the ubiquitin-proteasome system. This compound is instrumental in the development of novel therapeutic agents by enabling the synthesis of specific degradation probes, such as CW-3308. Its application in chemical biology extends to enhancing the understanding of protein dynamics and function in cellular processes. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C11-Br is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived CRBN ligand with a specialized linker utilized in PROTAC technology. This compound enables the targeted degradation of proteins by facilitating the formation of PROTAC EZH2 Degrader-23, thereby enhancing research into targeted protein degradation mechanisms. Its application in drug discovery and development provides a valuable tool for studying protein regulation and therapeutic interventions. -
E3 Ubiquitin Ligase Ligands and Linkers for PROTACs
E3 Ligase Ligand-linker Conjugate 139 is designed to bind to E3 ubiquitin ligases, serving as a critical component in the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates ubiquitination and subsequent degradation of target proteins, making it a valuable tool for cancer research and therapeutic applications. Its unique properties enable efficient disruption of protein homeostasis, offering insights into cellular pathways and potential treatment strategies in oncology. -
E3 Ligase Ligand-Linker Conjugates
5-Aminothalidomide-C9-Boc is a ligase ligand-linker conjugate targeting E3 ligases. It serves as a critical component in the synthesis of the PROTAC TRIB2 degrader-1, facilitating targeted protein degradation. This compound is essential for research applications involving small molecule-induced protein degradation and targeted therapy development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG3-NH2 is an E3 ligase ligand-linker conjugate featuring the cereblon ligand derived from Pomalidomide, combined with a PEG3 linker. This compound facilitates targeted protein degradation via PROTAC technology, enabling selective modulation of protein levels in cellular systems. It is valuable for research applications focused on understanding protein homeostasis and exploring therapeutic strategies in diseases involving dysregulated protein expression. -
E3 Ligase Ligand-linker Conjugate
Pomalidomide-NH-C13-OH is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC PI3Kα degrader-1, enabling the selective degradation of the PI3Kα protein. Its effective engagement with E3 ligases makes it a valuable tool for research in targeted therapies and the modulation of cellular protein levels. -
E3 Ubiquitinase Ligand-Linker Conjugate
Pomalidomide 4'-alkylC8-acid is an E3 ubiquitin ligase ligand-linker conjugate featuring Pomalidomide, a third-generation immunomodulator. This compound functions as a molecular glue, binding to the E3 ligase cereblon and facilitating the degradation of the essential Ikaros transcription factor. It is valuable for research applications related to targeted protein degradation and understanding the regulatory mechanisms of immune response. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-PEG3-azide is an E3 ligase ligand-linker conjugate that facilitates the synthesis of proteolysis-targeting chimeras (PROTACs). This compound can be employed in studies aiming to degrade specific target proteins, including 11β-HSD1, thus providing insights into protein regulation and turnover mechanisms. It serves as a valuable tool for researchers investigating targeted protein degradation strategies in therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH is an E3 ligase ligand-linker conjugate featuring a VHL ligand. This compound is utilized in PROTAC (Proteolysis Targeting Chimeras) technology, which enables targeted protein degradation. Its design facilitates selective degradation of specific proteins, making it a valuable tool for studying protein function and developing therapeutic strategies in various diseases. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-CO-C9-NH2 hydrochloride is a von Hippel-Lindau (VHL) amino building block that serves as a crucial component for the synthesis of E3 ligase ligands. This compound functions as a linker in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation. Its key biological activity supports research in cellular signaling, protein homeostasis, and therapeutic development for various diseases. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-5-C7-NH2 serves as an E3 ligase ligand-linker conjugate, utilizing a 5-Aminothalidomide-derived CRBN ligand. This compound is designed to facilitate the development of proteolysis-targeting chimeras (PROTACs), specifically enabling the synthesis of BT-O2C. Its application in protein regulation research underscores its potential in therapeutic strategies targeting E3 ligase-mediated degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 54 is a conjugate composed of Thalidomide and a specific linker, designed to target the E3 ligase Cereblon (CRBN). This compound facilitates the recruitment of CRBN, serving as a crucial intermediate in the development of PROTAC (Proteolysis Targeting Chimeras) molecules. E3 Ligase Ligand-Linker Conjugate 54 is valuable for research focused on targeted protein degradation and E3 ligase modulation, enhancing the understanding of cellular protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-amide-pimelic acid serves as an E3 ligase ligand-linker conjugate, incorporating the Lenalidomide-derived CRBN ligand and a specialized linker. This compound is essential for the synthesis of PROTAC MNK1 degrader-1, facilitating targeted protein degradation via the ubiquitin-proteasome pathway. Its application enhances research into targeted therapies and the modulation of gene expression through protein degradation. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-7-bromohept-1-yne serves as an E3 ligase ligand-linker conjugate, facilitating the development of proteolysis-targeting chimeras (PROTACs). This compound is essential for targeted protein degradation research, allowing the selective modulation of protein levels in cellular systems. Its unique structure aids in enhancing therapeutic strategies by harnessing the ubiquitin-proteasome pathway for targeted degradation of specific proteins. -
E3 ligase ligand-linker conjugate
Pomalidomide-5'-C8-acid is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN) ligand derived from Pomalidomide. This compound is designed for use in the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. Its unique structure allows for efficient engagement with E3 ligases, making it a valuable tool in molecular biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 34 is a compound that combines an E3 ligase ligand with a linker, specifically integrating Thalidomide to facilitate the recruitment of Cereblon (CRBN) proteins. This conjugate plays a crucial role in the development of PROTAC molecules, serving as an essential intermediate in targeted protein degradation research. Its applications are significant in studying E3 ligase-mediated ubiquitination and protein regulation pathways. -
Ligand for E3 Ligase
Pomalidomide-5-C9-NH2 hydrochloride is a potent ligand targeting the E3 ligase cereblon (CRBN). This compound facilitates the recruitment of CRBN protein, enabling targeted protein degradation. It serves as a valuable tool in the development of PROTACs (proteolysis-targeting chimeras) by linking with other ligands, thereby advancing research in cellular regulation and cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
JQ-1 carboxylic acid-PEG3-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed for use in PROTAC (proteolysis-targeting chimera) synthesis. This compound facilitates targeted protein degradation by linking E3 ligases to proteins of interest, thereby enabling selective modulation of protein levels. It serves as a valuable tool in the investigation of protein regulation and therapeutic intervention strategies in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-C7-NH2 is an E3 ligase ligand-linker conjugate that facilitates the development of proteolysis-targeting chimeras (PROTACs). It serves as a crucial component for targeted protein degradation, enabling selective modulation of protein levels in various biological contexts. This compound is valuable for research applications in targeted therapy development and interrogation of cellular pathways involving E3 ligase interactions. -
Conjugate
(S,R,S)-AHPC-Me-CO-C9-NH2 is a versatile E3 ligase ligand utilized as a PROTAC linker. This conjugate enables the formation of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation in various cellular contexts. Its application in research is pivotal for studying protein interactions and developing novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-Linker Conjugate 183 is designed to target E3 ligases, facilitating the selective degradation of protein substrates through the ubiquitin-proteasome system. This conjugate features the LC3B ligand 2, which enhances autophagic degradation, and an optimized linker for effective delivery. Its applications include studies on protein turnover, cellular homeostasis, and targeted protein degradation, particularly in the context of PCSK9 regulation. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide 4'-alkylC3-acid is an E3 ligase ligand-linker conjugate that specifically engages the cereblon (CRBN) protein. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling targeted protein degradation. It is a valuable tool for researchers studying protein homeostasis and developing innovative therapeutic strategies in various disease models. -
LCL-PEG3-N3 (hydrochloride) Decoy Oligonucleotide Ligand
LCL-PEG3-N3 hydrochloride is a decoy oligonucleotide ligand targeting E3 ligases, facilitating the development of chimeric molecules such as LCL-ER(dec) for the degradation of estrogen receptors. This compound features an azide functional group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with alkyne-bearing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with reagents containing DBCO or BCN groups, making it a versatile tool for click chemistry applications in chemical biology research. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C7-NH2 is an E3 ligase ligand-linker conjugate featuring Pomalidomide conjugated to a C7 amine linker. This compound serves as a valuable building block for the synthesis of proteolysis targeting chimeras (PROTACs), facilitating targeted protein degradation. Through its targeted interaction with E3 ligases, Pomalidomide-C7-NH2 is instrumental in advancing research in protein regulation and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
Pomalidomide-C6-NHS ester is a synthesized E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand connected through an NHS ester linker. This compound is designed for use in protein degradation studies, allowing for targeted ubiquitination and subsequent proteasomal degradation of specific proteins. Its applications include exploring the mechanisms of protein homeostasis and aiding in the development of novel therapeutics through targeted protein manipulation. -
Ligand for E3 Ligase
Pomalidomide-5-C10-NH2 hydrochloride is a derivative of Pomalidomide that functions as a ligand for the E3 ubiquitin ligase cereblon (CRBN). This compound facilitates the targeted recruitment of CRBN, enabling the formation of PROTAC (proteolysis-targeting chimeras) when linked to a specific protein ligand. Pomalidomide-5-C10-NH2 hydrochloride is suitable for research applications focused on protein degradation pathways and targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-piperidineacetaldehyde is an E3 ligase ligand-linker conjugate that engages specific E3 ligases for targeted protein degradation. This reagent serves as a critical component in the synthesis of proteolysis-targeting chimera (PROTAC) H122, facilitating the selective elimination of proteins of interest. Its application supports research in protein regulation and dynamics, with implications for therapeutic development in various disease models. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is an E3 ligase ligand-linker conjugate that harnesses the cereblon-targeting capabilities of thalidomide. This compound serves as a crucial component in the synthesis of PROTACs, specifically facilitating the degradation of BET proteins. Its unique structure enables selective engagement with E3 ligases, making it a valuable tool for researchers investigating targeted protein degradation and related therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
Dione-piperidine-indazol-piperazin-cyclohexyl-NH2 functions as an E3 ligase ligand-linker conjugate, effectively combining a CRBN ligand with a suitable linker. This compound is pivotal for the synthesis of PROTAC MD-4251, facilitating targeted protein degradation in cellular research. Its unique structure allows for efficient engagement with E3 ligases, providing valuable insight into protein modulation and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 45 is an innovative conjugate composed of an E3 ligase ligand and a linker, featuring Thalidomide as a key component. It functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein. This conjugate serves as a critical intermediate in the synthesis of complete PROTAC molecules, thus enabling targeted protein degradation research and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
A 410099.1 amide-PEG2-amine-Boc is a functionalized ligand designed for E3 ligase targeting, specifically utilized in PROTAC (Proteolysis Targeting Chimeras) applications. This compound features an IAP ligand combined with a PEG2 linker and a terminal amine, enabling efficient conjugation with target protein ligands. Its design facilitates targeted protein degradation, making it a valuable tool for studying protein function and developing novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide 5'-piperazine-4-methylpiperidine functions as an E3 ligase ligand-linker conjugate, facilitating targeted protein degradation. This compound is instrumental in the synthesis of PROTACs, including the development of PROTAC EGFR degrader 13. Its unique structural properties enable the targeted modulation of protein levels, making it valuable for research in therapeutic strategies that leverage the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-amido-C4-Br is a versatile E3 ligase ligand-linker conjugate designed for the synthesis of protein-targeting chimeras, specifically PROTAC degraders such as BSJ-02-162. This compound facilitates targeted protein degradation through the engagement of E3 ligases, thereby modulating protein levels in various biological contexts. It is an essential tool for researchers developing innovative therapies that leverage targeted ubiquitination and degradation pathways. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C12-Br is a synthesized E3 ligase ligand-linker conjugate featuring a Thalidomide-based CRBN ligand. It serves as a crucial component in PROTAC technology, enabling the targeted degradation of proteins. This compound facilitates the assembly of PROTACs, such as EZH2 Degrader-24, and is instrumental in research focused on protein regulation and therapeutic development. -
E3 Ligase Ligand Linker Conjugate
(S,R,S)-AHPC-C7-amine hydrochloride is a novel E3 ligase ligand-linker conjugate that combines a VH032-derived VHL ligand with a C7 linker for targeted protein degradation. Its design facilitates the development of PROTACs targeting estrogen-related receptor α (ERRα), highlighting its utility in research on protein modulation and degradation pathways. This compound serves as a valuable tool in the study of E3 ligase-mediated degradation mechanisms and therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-C13-piperazine-Boc is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC degraders, specifically NC-R17. This compound facilitates targeted protein degradation by connecting a ligand for E3 ligases to a protein of interest. Its application in PROTAC technology enables the modulation of protein levels, making it a valuable tool for researchers studying protein regulation and therapeutic degradation strategies. -
E3 Ligase Ligand-Linker Conjugates
(S,S,S)-VH032-cyclopropane-F-C4-aldehyde is an E3 ligase ligand-linker conjugate designed for use in the synthesis of PROTAC compounds, specifically cis-VZ185. This reagent facilitates targeted protein degradation by engaging with the ubiquitin-proteasome system, making it a valuable tool for researchers investigating protein modulation and degradation pathways. Its unique structure allows for precise conjugation in drug discovery applications focused on cancer and other diseases influenced by protein dysregulation. -
E3 Ligase Ligand-linker Conjugatecan
Boc-4-(3-oxobutyl)piperidine-(S,R,S)-AHPC is a ligand-linker conjugate designed for targeting E3 ligases in protein degradation applications. This compound facilitates the development of proteolysis targeting chimeras (PROTACs), specifically in the synthesis of BRD2 BD1 Degrader-1. It plays a crucial role in selective protein degradation research and expanding therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 176 is designed to bind specifically to E3 ligases, facilitating targeted protein degradation through the ubiquitin-proteasome system. This conjugate enables the synthesis of BMS-986458, allowing for further exploration of E3 ligase modulation in various biological contexts. It is essential for studies focused on protein homeostasis and the therapeutic potential of targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugate
Deoxy-thalidomide-C4-NH2 is a ligand-linker conjugate targeting the E3 ligase Cereblon (CRBN). This compound facilitates the development of Proteolysis Targeting Chimeras (PROTACs), specifically for synthesizing BRD4 degraders. Its unique structure supports targeted protein degradation, making it a valuable tool for research in cellular protein regulation and therapeutics. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-S-C6-acid is a synthetic E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a C6 linker. This compound facilitates the development of PROTACs, specifically designed for targeted protein degradation applications, including the synthesis of the PROTAC Cas9 Degrader-1. Its ability to engage with E3 ligases makes it a valuable tool in biochemistry and molecular biology research focused on therapeutic interventions through targeted protein modulation. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 174 is a specialized reagent designed to target E3 ligases through a ligand-linker conjugate. This compound facilitates the synthesis of the potent compound TYD-68, enabling researchers to explore the role of E3 ligases in ubiquitination processes. Its application in chemical biology can aid in the development of targeted therapies and the study of protein degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-Pip-butyn is an E3 ligase ligand-linker conjugate derived from Lenalidomide. It effectively recruits the CRBN protein, facilitating targeted protein degradation through the formation of proteolysis-targeting chimeras (PROTACs). This reagent is particularly useful for creating PROTACs like the STAT3 degrader SD-436, enabling studies on protein regulation and degradation pathways in cellular models. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG3-COOH is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation via the cereblon pathway. This compound integrates a Thalidomide-derived cereblon ligand with a PEG3 linker, optimizing its application in PROTAC (Proteolysis Targeting Chimera) technology. Its unique structure enhances cellular interaction and degradation of specific target proteins, making it a valuable tool for researchers investigating protein regulation and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 218 is designed as a specific ligand-linker construct targeting E3 ligases. This compound plays a crucial role in the development of PROTACs, specifically in the synthesis of STAT6 degrader-2. Researchers can utilize this conjugate to facilitate targeted protein degradation, enhancing studies in protein homeostasis and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-OH-C11-OH is an E3 ligase ligand-linker conjugate designed to recruit the cereblon (CRBN) protein. This compound serves as a crucial intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs), including various targeted degraders. Its application in the development of PROTACs facilitates targeted protein degradation, providing insights into cellular mechanisms and therapeutic opportunities in various diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 170 is a specialized conjugate that facilitates the synthesis of PROTACs by incorporating an E3 ligase ligand with a linker. This compound demonstrates potent anti-proliferative activity in non-Hodgkin's lymphoma cell line SU-DHL-4, exhibiting an IC50 value of less than 0.2 μM. It is an essential tool for researchers investigating targeted protein degradation pathways and their implications in cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-Glycolic acid is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound facilitates the targeted degradation of specific proteins, most notably as a component in the FLT3 degrader LWY713. Its application in research focuses on understanding protein homeostasis and the modulation of oncogenic pathways, making it a valuable tool for drug development in cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C2-piperazine-Boc is an E3 ligase ligand-linker conjugate designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs). This compound facilitates targeted degradation of proteins, enabling researchers to manipulate cellular pathways and study protein function. It serves as a key component in the development of PROTACs, such as PROTAC BET Degrader-15, offering significant potential for applications in therapeutic research and drug discovery. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 115 is a potent E3 ubiquitin ligase ligand combined with a linker, designed for the development of targeted protein degradation strategies. This compound serves as a crucial component in synthesizing PROTAC SMARCA2/4-degrader-27, enabling researchers to investigate the modulation of specific protein levels through ubiquitin-proteasome pathway engagement. Its application in chemical biology provides a valuable tool for studying protein function and regulation in various cellular contexts.
